| External factors: | ABT-263 |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experimental category: | L |
| Tissue type: | -- |
| Cell name: | SK-BR-7,U2OS,A549,HCC712,MDA-MB-175,MCF-7 |
| PMID: | 32457483 |
| Experiment: | Western blot//Immunoblotting//Immunofluorescence//Microscopy//Gene editing |
| Description: | Treatment with appropriate senolytic drugs induced strong activation of caspase 3, as detected by immunofluorescence staining and immunoblot, but only in senescent cells.Time course microscopy confirmed doxorubicin-induced senescent 4226 and MDA-MB-175 cells underwent rapid and near-synchronous cell death when treated with ABT-263 or ABT-263/S63845. To verify the role of BCL-XL and MCL1 in survival of senescent MCF-7 A/S-sensitive cells, we infected with CRISPR/Cas9 lentivirus and guide RNAs targeting either BCL2L1 (BCL-XL) or MCL1, and hypothesized edited cells would die when treated with only the MCL1 inhibitor S63845 or ABT-263, respectively. This hypothesis was supported as the number of senescent MCF-7 BCL2L1-sg cells was significantly reduced with S63845 alone, and senescent MCF-7 MCL1-sg cell number was reduced by treatment with ABT-263 alone. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: